Cerebral sinus thrombosis in a patient with humoral immunodeficiency on intravenous immunoglobulin therapy: A case report

Neuropediatrics

Volumn 39, Issue 2, 2008, Pages 131-133

  Barada, W ^a   Muwakkit, S ^a   Hourani, R ^a   Bitar, M ^a   Mikati, M ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Bruton's disease; Dural sinus thrombosis; Intravenous immuno globulins

Indexed keywords

ACETYLSALICYLIC ACID; CD19 ANTIGEN; IMMUNOGLOBULIN G; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

APHASIA; ARTICLE; B LYMPHOCYTE; CASE REPORT; CEREBRAL SINUS THROMBOSIS; CONNECTIVE TISSUE DISEASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; FLOW CYTOMETRY; HUMAN; HUMORAL IMMUNE DEFICIENCY; INTERNATIONAL NORMALIZED RATIO; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PHLEBOGRAPHY; PRIORITY JOURNAL; SCHOOL CHILD; T LYMPHOCYTE; THROMBOPHILIA; WEAKNESS;

CHILD; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; MALE; PHLEBOGRAPHY; SINUS THROMBOSIS, INTRACRANIAL; TOMOGRAPHY, X-RAY COMPUTED;

EID: 50649099426     PISSN: 0174304X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2008-1077088     Document Type: Article

References (11)

1. Alper F, Kantarci M, Dane S, Gumustekin K, Onbas O, Durur I. Importance of anatomical asymmetries of transverse sinuses: an MR venographic study. Cerebrovasc Dis 2004; 18: 236-239
2. Caress JB, Cartwright MS, Donofrio PD, Peacock Jr JE. The clinical features of 16 cases of stroke associated with administration of IVIG. Neurology 2003; 60: 1822-1824
3. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994; 44: 223-226
4. Dalakas MC, Clark WM. Strokes, thromboembolic events, and IVIG, Rare incidents blemish an excellent safety record. Neurology 2003; 60: 1736-1737
5. Evangelou N, Littlewood T, Anslow P, Chapel H. Transverse sinus thrombosis and IVIG treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment. J Clin Pathol 2003; 56: 308-309
6. FDA. Interim statement regarding immune globulin intravenous (IGIV) August 27, 2002: www.fda.gov/cber/infosheets/IVIG082702.htm
7. Hefer D, Jaloudi M. Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature. Ann Hematol 2004; 83: 661-665
8. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345: 747-755
9. Zaidan R, Al Moallem M, Wani BA, Shameena AR, Al Tahan AR, Daif AK. Thrombosis complicating high-dose intravenous immunoglobulin: report of three cases and review of the literature. Eur J Neurol 2003: 10: 367-372
10. Wada Y, Kamei A, Fujii Y, Ishikawa K, Chida S. Cerebral infarction after high-dose intravenous immunoglobulin therapy for Kawasaki disease. J Pediatr 2006; 148: 399-400
11. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000; 65: 30-34